Weight Management with GLP-1 Receptor Agonists

Mechanism of Action and Efficacy

The American College of Cardiology and other guideline societies may recommend GLP-1 receptor agonists, such as liraglutide and semaglutide, for weight management, as they work by suppressing appetite, delaying gastric emptying, and increasing satiety 2
Liraglutide has 97% homology to human GLP-1, and both medications act on the hypothalamus to control appetite and food intake 2, 1
Semaglutide demonstrates superior weight loss efficacy, with a mean weight loss of 14.9-16.0% at 68 weeks 1
The American Heart Association may support the use of semaglutide, which produces approximately 15% weight loss compared to 5-8% with liraglutide 3.0mg 1

The Endocrine Society recommends administering liraglutide as a once-daily subcutaneous injection, with a dosing schedule that starts at 0.6 mg daily for 1 week and increases by 0.6 mg weekly 3, 2, 4
The American Gastroenterological Association may suggest that semaglutide is administered as a once-weekly subcutaneous injection, with a dosing schedule that starts at 0.25 mg weekly for 4 weeks and increases to 2.4 mg weekly 4
Both medications have similar adverse effect profiles, primarily gastrointestinal symptoms, including nausea, vomiting, diarrhea, constipation, and headache 2, 3

The American Association of Clinical Endocrinologists recommends that both medications are indicated for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, and should be used as adjuncts to reduced-calorie diet and increased physical activity 3, 2
Gradual dose titration is essential for both medications to minimize gastrointestinal side effects, and both medications require long-term use to maintain weight loss benefits 4, 1
Patients with type 2 diabetes may particularly benefit from these medications due to their glucose-lowering effects 3, 4